Last 12 months
Inside the activity.
0 purchase rows · 14 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 2, 2026 21:50 UTC |
Heyman Richard A.Director
|
Exercise / conversionStock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001584759-26-000017 · form4-10022026_091044.xml · derivative · entry 4 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,700 Underlying: Common Stock · 3,500 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| October 01, 2026 Filed Oct 2, 2026 21:50 UTC |
Heyman Richard A.Director
|
SaleCommon Stock | 3,200 | $12.91 | $41,325.12 |
DisclosureSEC source: 0001584759-26-000017 · form4-10022026_091044.xml · nonDerivative · entry 3 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 203,472 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC. F2 · price: This transaction was executed in multiple trades at prices ranging from $12.57 to $13.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares. Read SEC document |
| October 01, 2026 Filed Oct 2, 2026 21:50 UTC |
Heyman Richard A.Director
|
SaleCommon Stock | 3,500 | $12.91 | $45,199.35 |
DisclosureSEC source: 0001584759-26-000017 · form4-10022026_091044.xml · nonDerivative · entry 2 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,300 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC. F2 · price: This transaction was executed in multiple trades at prices ranging from $12.57 to $13.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2026 Filed Oct 2, 2026 21:50 UTC |
Heyman Richard A.Director
|
Exercise / conversionCommon Stock | 3,500 | $1.60 | $5,600.00 |
DisclosureSEC source: 0001584759-26-000017 · form4-10022026_091044.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 23:59 UTC |
Piscitelli DominicChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 600 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001695028-26-000008 · form4-09252026_110926.xml · derivative · entry 4 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,900 Underlying: Common Stock · 600 shares Expires 2032-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 23:59 UTC |
Piscitelli DominicChief Financial Officer
|
SaleCommon Stock | 500 | $13.51 | $6,752.50 |
DisclosureSEC source: 0001695028-26-000008 · form4-09252026_110926.xml · nonDerivative · entry 3 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,828 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 23:59 UTC |
Piscitelli DominicChief Financial Officer
|
SaleCommon Stock | 100 | $13.50 | $1,350.00 |
DisclosureSEC source: 0001695028-26-000008 · form4-09252026_110926.xml · nonDerivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,328 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 23:59 UTC |
Piscitelli DominicChief Financial Officer
|
Exercise / conversionCommon Stock | 600 | $4.36 | $2,616.00 |
DisclosureSEC source: 0001695028-26-000008 · form4-09252026_110926.xml · nonDerivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 16:11 UTC |
Piscitelli DominicChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001695028-26-000006 · form4-08282026_080834.xml · derivative · entry 5 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 25,000 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vested on February 1, 2024, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 16:11 UTC |
Piscitelli DominicChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 52,000 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001695028-26-000006 · form4-08282026_080834.xml · derivative · entry 4 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,500 Underlying: Common Stock · 52,000 shares Expires 2032-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 16:11 UTC |
Piscitelli DominicChief Financial Officer
|
SaleCommon Stock | 77,000 | $13.69 | $1,053,814.30 |
DisclosureSEC source: 0001695028-26-000006 · form4-08282026_080834.xml · nonDerivative · entry 3 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,828 F2 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 16:11 UTC |
Piscitelli DominicChief Financial Officer
|
Exercise / conversionCommon Stock | 25,000 | $6.00 | $150,000.00 |
DisclosureSEC source: 0001695028-26-000006 · form4-08282026_080834.xml · nonDerivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 16:11 UTC |
Piscitelli DominicChief Financial Officer
|
Exercise / conversionCommon Stock | 52,000 | $4.36 | $226,720.00 |
DisclosureSEC source: 0001695028-26-000006 · form4-08282026_080834.xml · nonDerivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,680 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| July 24, 2026 Filed Jul 28, 2026 20:15 UTC |
Heyman Richard A.Director
|
Exercise / conversionStock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001584759-26-000015 · form4-07282026_080709.xml · derivative · entry 4 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,200 Underlying: Common Stock · 3,500 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| July 24, 2026 Filed Jul 28, 2026 20:15 UTC |
Heyman Richard A.Director
|
SaleCommon Stock | 6,100 | $12.02 | $73,322.00 |
DisclosureSEC source: 0001584759-26-000015 · form4-07282026_080709.xml · nonDerivative · entry 3 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 206,672 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC. F2 · ownership.nature: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares. Read SEC document |
| July 24, 2026 Filed Jul 28, 2026 20:15 UTC |
Heyman Richard A.Director
|
SaleCommon Stock | 7,000 | $12.02 | $84,140.00 |
DisclosureSEC source: 0001584759-26-000015 · form4-07282026_080709.xml · nonDerivative · entry 2 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,300 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC. Read SEC document |
| July 24, 2026 Filed Jul 28, 2026 20:15 UTC |
Heyman Richard A.Director
|
Exercise / conversionCommon Stock | 3,500 | $1.60 | $5,600.00 |
DisclosureSEC source: 0001584759-26-000015 · form4-07282026_080709.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 20:35 UTC |
Heyman Richard A.Director
|
SaleCommon Stock | 300 | $12.00 | $3,600.00 |
DisclosureSEC source: 0001584759-26-000012 · form4-07082026_080727.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 212,772 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC. F2 · ownership.nature: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:47 UTC |
Piscitelli DominicChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 52,000 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001695028-26-000004 · form4-02262026_090218.xml · derivative · entry 3 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,500 Underlying: Common Stock · 52,000 shares Expires 2032-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:47 UTC |
Piscitelli DominicChief Financial Officer
|
SaleCommon Stock | 52,000 | $13.51 | $702,686.40 |
DisclosureSEC source: 0001695028-26-000004 · form4-02262026_090218.xml · nonDerivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,148 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2025. F2 · price: Represents the weighted average share price of an aggregate total of 52,000 shares sold in the price range of $13.50 to $13.53 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:47 UTC |
Piscitelli DominicChief Financial Officer
|
Exercise / conversionCommon Stock | 52,000 | $4.36 | $226,720.00 |
DisclosureSEC source: 0001695028-26-000004 · form4-02262026_090218.xml · nonDerivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 00:19 UTC |
Heyman Richard A.Director
|
SaleCommon Stock | 3,200 | $12.00 | $38,414.72 |
DisclosureSEC source: 0001584759-26-000006 · form4-01212026_120124.xml · nonDerivative · entry 2 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 213,072 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC. F2 · price: Represents the weighted average share price of an aggregate total of 6,700 shares sold in the price range of $12.00 to $12.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 00:19 UTC |
Heyman Richard A.Director
|
SaleCommon Stock | 3,500 | $12.00 | $42,016.10 |
DisclosureSEC source: 0001584759-26-000006 · form4-01212026_120124.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,800 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC. F2 · price: Represents the weighted average share price of an aggregate total of 6,700 shares sold in the price range of $12.00 to $12.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:42 UTC |
Piscitelli DominicChief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 34,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001695028-26-000002 · form4-01062026_090131.xml · derivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,500 Underlying: Common Stock · 34,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3 · derivative.exercise_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028. F3 · derivative.expiration_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:42 UTC |
Piscitelli DominicChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 206,500 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0001695028-26-000002 · form4-01062026_090131.xml · derivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,500 Underlying: Common Stock · 206,500 shares Expires 2036-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 2, 2027, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:40 UTC |
Chacko JacobDirector · PRESIDENT AND CEO
|
GrantRestricted Stock Unit · Derivative | 112,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001608936-26-000002 · form4-01062026_090105.xml · derivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3 · derivative.exercise_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028. F3 · derivative.expiration_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:40 UTC |
Chacko JacobDirector · PRESIDENT AND CEO
|
GrantStock Option (right to buy) · Derivative | 675,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0001608936-26-000002 · form4-01062026_090105.xml · derivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 675,000 Underlying: Common Stock · 675,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 2, 2027, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:47 UTC |
Hoerter Steven L.Director
|
GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0001533451-26-000002 · form4-01062026_090105.xml · derivative · entry 1 Hoerter Steven L. · CIK 0001533451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:48 UTC |
Kunkel Lori AnneDirector
|
GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0001536368-26-000002 · form4-01062026_090157.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 16:44 UTC |
Dier MardiDirector
|
GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0001574591-26-000002 · form4-01062026_090138.xml · derivative · entry 1 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:46 UTC |
Heyman Richard A.Director
|
GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0001584759-26-000003 · form4-01062026_090104.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:41 UTC |
Multani Pratik SChief Medical Officer
|
GrantRestricted Stock Unit · Derivative | 35,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001586894-26-000002 · form4-01062026_090111.xml · derivative · entry 2 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,500 Underlying: Common Stock · 35,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3 · derivative.exercise_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028. F3 · derivative.expiration_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:41 UTC |
Multani Pratik SChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 214,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0001586894-26-000002 · form4-01062026_090111.xml · derivative · entry 1 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,000 Underlying: Common Stock · 214,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 2, 2027, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:49 UTC |
You AngieDirector
|
GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0001647664-26-000002 · form4-01062026_090103.xml · derivative · entry 1 You Angie · CIK 0001647664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 00:19 UTC |
Piscitelli DominicChief Financial Officer
|
SaleCommon Stock | 10,720 | $9.06 | $97,127.49 |
DisclosureSEC source: 0001695028-25-000008 · form4-12182025_121249.xml · nonDerivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,148 F3 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 10,720 shares sold in the price range of $9.0396 to $9.1953 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 00:18 UTC |
Chacko JacobDirector · PRESIDENT AND CEO
|
SaleCommon Stock | 33,374 | $9.06 | $302,368.44 |
DisclosureSEC source: 0001608936-25-000014 · form4-12182025_121249.xml · nonDerivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 581,711 F2 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. F3 · price: Represents the weighted average share price of an aggregate total of 33,374 shares sold in the price range of $9.0257 to $9.095 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 00:21 UTC |
Multani Pratik SChief Medical Officer
|
SaleCommon Stock | 10,720 | $9.06 | $97,128.56 |
DisclosureSEC source: 0001586894-25-000005 · form4-12182025_121256.xml · nonDerivative · entry 2 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,149 F3 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 10,720 shares sold in the price range of $9.0449 to $9.1451 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:19 UTC |
Piscitelli DominicChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 11,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001695028-25-000008 · form4-12182025_121249.xml · derivative · entry 5 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,667 Underlying: Common Stock · 11,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F7 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027. F7 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:19 UTC |
Piscitelli DominicChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001695028-25-000008 · form4-12182025_121249.xml · derivative · entry 4 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F6 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. F6 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:19 UTC |
Piscitelli DominicChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001695028-25-000008 · form4-12182025_121249.xml · derivative · entry 3 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F5 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. F5 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:19 UTC |
Piscitelli DominicChief Financial Officer
|
Exercise / conversionCommon Stock | 29,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001695028-25-000008 · form4-12182025_121249.xml · nonDerivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F2 · balance_after: Includes 1,218 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:18 UTC |
Chacko JacobDirector · PRESIDENT AND CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 33,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001608936-25-000014 · form4-12182025_121249.xml · derivative · entry 5 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,667 Underlying: Common Stock · 33,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F6 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027. F6 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:18 UTC |
Chacko JacobDirector · PRESIDENT AND CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 28,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001608936-25-000014 · form4-12182025_121249.xml · derivative · entry 4 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,334 Underlying: Common Stock · 28,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F5 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. F5 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:18 UTC |
Chacko JacobDirector · PRESIDENT AND CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001608936-25-000014 · form4-12182025_121249.xml · derivative · entry 3 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F4 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. F4 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:18 UTC |
Chacko JacobDirector · PRESIDENT AND CEO
|
Exercise / conversionCommon Stock | 83,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001608936-25-000014 · form4-12182025_121249.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 615,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:21 UTC |
Multani Pratik SChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 11,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001586894-25-000005 · form4-12182025_121256.xml · derivative · entry 5 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,667 Underlying: Common Stock · 11,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F7 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027. F7 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:21 UTC |
Multani Pratik SChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001586894-25-000005 · form4-12182025_121256.xml · derivative · entry 4 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F6 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. F6 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:21 UTC |
Multani Pratik SChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001586894-25-000005 · form4-12182025_121256.xml · derivative · entry 3 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F5 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. F5 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:21 UTC |
Multani Pratik SChief Medical Officer
|
Exercise / conversionCommon Stock | 29,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001586894-25-000005 · form4-12182025_121256.xml · nonDerivative · entry 1 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F2 · balance_after: Includes an aggregate of 2,771 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 22:35 UTC |
Kunkel Lori AnneDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001536368-25-000006 · form4-12092025_101258.xml · derivative · entry 2 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,600 Underlying: Common Stock · 10,000 shares Expires 2034-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 12, 2025 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.